Target Group Inc. (CBDY)
OTHER OTC:CBDY
Top Page
No summary available
Positive Factors
Revenue Growth
Significant revenue growth indicates strong market demand and effective sales strategies, enhancing long-term business prospects.
Negative Factors
Net Profit Margin
A modest net profit margin indicates challenges in translating revenue growth into substantial profits, impacting long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Significant revenue growth indicates strong market demand and effective sales strategies, enhancing long-term business prospects.
Read all positive factors
Target Group (CBDY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.11M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth-24.89%
EPS Growth-150.00%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding617,026,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.24
P/FCF Ratio-1.10
Enterprise Value/Market Cap1.56
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit0.84
Enterprise Value/Ebitda2.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Target Group Business Overview & Revenue Model
Company Description
Target Group Inc. cultivates, processes, and distributes curated cannabis products for the adult-use medical and recreational cannabis market in Canada. Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k...
How the Company Makes Money
Target Group (CBDY) generates revenue through the sale of its CBD-based products across various distribution channels, including online platforms, retail partnerships, and direct-to-consumer sales. The company capitalizes on the growing demand for...
Target Group Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.88M | 6.59M | 3.72M | 0.00 | 0.00 |
| Gross Profit | 2.07M | 3.73M | 1.66M | -885.00K | -972.00K |
| EBITDA | 582.94K | 2.23M | 1.95M | -453.00K | -359.00K |
| Net Income | -1.36M | 160.50K | -324.00K | -4.52M | -471.00K |
Balance Sheet | |||||
| Total Assets | 3.85M | 7.57M | 8.84M | 7.57M | 13.06M |
| Cash, Cash Equivalents and Short-Term Investments | 100.41K | 1.87M | 736.32K | 223.84K | 113.08K |
| Total Debt | 1.03M | 10.98M | 1.35M | 1.43M | 1.63M |
| Total Liabilities | 858.09K | 14.08M | 15.81M | 14.13M | 15.22M |
| Stockholders Equity | 2.99M | -6.51M | -6.97M | -6.56M | -2.15M |
Cash Flow | |||||
| Free Cash Flow | -842.42K | 2.09M | -611.70K | -1.02M | 100.12K |
| Operating Cash Flow | -842.42K | 2.16M | -589.61K | -1.01M | 100.12K |
| Investing Cash Flow | 81.38K | -178.98K | 416.93K | 1.02M | -1.41M |
| Financing Cash Flow | -1.06M | -730.23K | 666.90K | 122.67K | 1.25M |
Target Group Risk Analysis
Target Group disclosed 13 risk factors in its most recent earnings report. Target Group reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Target Group Peers Comparison
UnderperformOutperform
Sector (51)
CBDY
Target Group
―
―
―
PRFX
PainReform
2.25
-6.49
-74.26%
DRMA
Dermata Therapeutics
1.35
-7.03
-83.89%
CERO
CERo Therapeutics Holdings
0.03
-14.07
-99.77%
PBM
Psyence Biomedical
2.50
-19.44
-88.60%
CDT
CDT Equity
4.22
-1,765.78
-99.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―